Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma

Table 2 Serum α-fetoprotein level of different tumor related factors n (%)

Variables	n = 2304	AFP (μg/L)	P value
HBV infection			< 0.001
Yes	1875 (81.4)	573.9 ± 547.7
No	429 (18.6)	398.4 ± 522.3
Tumor size(cm)			< 0.001
≤ 5	871 (37.8)	444.9 ± 514.2
5-10	804 (34.9)	499.5 ± 536.4
≥ 10	629 (27.3)	808.4 ± 529.2
Tumor number			0.451
1	1666 (72.2)	531.9 ± 18.9
2	288 (12.5)	532.2 ± 44.7
≥ 3	350 (15.3)	556.0 ± 42.2
Vascular invasion			< 0.001
No	1714 (74.4)	502.1 ± 543.1
Yes	590 (25.6)	694.1 ± 546.9
Tumor differentiation1			0.007
High	139 (7.5)	207.3 ± 420.8
Intermediateb	963 (52.3)	527.9 ± 538.4
Low	741 (40.2)	559.2 ± 545.7
TNM staging			0.306
I	495 (21.5)	578.6 ± 549.3
II	289 (12.5)	493.3 ± 542.2
IIIA	726 (31.5)	548.6 ± 544.3
IIIB	214 (9.3)	585.3 ± 553.4
IIIC	101 (4.3)	558.9 ± 551.7
IV	479 (20.8)	534.0 ± 545.9
BCLC staging			0.008
A	869 (37.7)	506.2 ± 537.4
B	251 (10.9)	590.1 ± 551.1
C	1028 (44.6)	607.3 ± 553.3
Dd	156 (6.8)	625.7 ± 529.8
China staging			0.386
I	137 (5.9)	487.8 ± 542.2
IIa	198 (8.6)	528.8 ± 533.9
IIb	893 (38.7)	560.8 ± 545.7
III	1076 (46.7)	527.9 ± 544.8

¹We assessed 1843/2304 patients who had underwent hepatectomy or fine needle aspiration.

^bP < 0.001 vs high and low differentiation groups.

^dP < 0.001 vs stage A and B of BCLC. AFP: α-fetoprotein; HBV: Hepatitis B virus; TNM: Tumor-node-metastasis; BCLC: The Barcelona-Clinic Liver Cancer Group.